Forty-seven patients with probable Alzheimer disease (AD) completed a 6-month double-blind
study to compare metrifonate with placebo. The Alzheimer Disease Assessment Scale …

Fifty patients with probable Alzheimer disease (AD) completed a 3-month double-blind study
to compare metrifonate to placebo. We dosed metrifonate to achieve a 40–60% inhibition of …

We studied the pharmacokinetics and pharmacodynamics [red blood cell (RBC) cholinesterase
(ChE) inhibition] of metrifonate (MTF) and its active anti-ChE metabolite, dichlorvos (…

We report high-performance liquid chromatographic methods using ultraviolet detection,
developed for the first time in our laboratory with sensitivity to detect clinically significant …

Physostigmine (Phy) was determined in plasma and cerebrospinal fluid (CSF) by HPLC
with electrochemical detection, with use of a normal-phase column and methanolic sodium …

… Becker RE, Moriearty PL, Unni LK. The second generation of cholinesterase inhibitors: …
Unni LK, Unni RK, Becker RE. A theoretical model to predict the pharmacodynamics of …

A physiological model for physostigmine disposition was developed in the rat which incorporated
anatomical, physiological, and biochemical parameters, ie tissue volume, plasma flow …

Physostigmine (Phy) was rapidly metabolized by rat liver after iv (100 micrograms/kg) or im (650
micrograms/kg) administration. The half-life of Phy in liver after iv and im administration …

Commercial priorities have been identified as negative factors in drug development. We trace
the problem to inattention to sound clinical pharmacology practices. When properly applied…

The binding of 3 H-physostigmine ( 3 H-Ph) to human and rat plasma proteins and
crystalline serum albumin was studied by ultrafiltration technique. This study showed that the …